cardiac remodeling; pressure overload; cathepsin B; apoptosis HEART FAILURE (HF) IS A LEADING cause of death in industrialized nations, especially in the aging population (19) . Cardiac remodeling is the process of structural and functional changes in the left ventricle (LV) in response to internal or external cardiovascular damage or induced by pathogenic risk factors, and it is a precursor of clinical heart failure (13) . The remodeling process affects not only cardiomyocytes but also interstitial tissue, fibroblasts, inflammatory cells, and endothelial cells, as well as the influence of these cells on both myocardial architecture and tissue repair (9) . Divergent signaling mechanisms lead to distinct patterns of cardiac remodeling. The mitogen-activated protein kinase (MAPK) (27) and Akt (1) signaling pathways and matrix metalloproteinases (MMPs) (14) regulate the extracellular matrix and wall stiffness, as well as cardiomyocyte apoptosis pathways (40) , including both the mitochondrial and endoplasmic reticulum stress pathways, leading to cell death and contributing to reduced cardiac contractility (21) . Inhibition of these pathways in the heart in the setting of increased biomechanical stress remains incompletely understood.
Lysosomal cathepsins are lysosomal proteases that belong to the papain family, which contains the following 11 members in humans: cathepsin B (CTSB), C, F, H, K, L, O, S, V, X, and W, which exist at the sequence level. They were initially considered intracellular enzymes, namely, enzymes responsible for the majority of proteolysis in the acidic environment of the endosomal/lysosomal compartment, a setting in which they degrade intracellular and extracellular proteins (33) . Many cathepsins are expressed in both developing and adult hearts. Previous studies have demonstrated that cathepsins are essential for both cardiomyocyte apoptosis (32) and extracellular matrix balance (22a, 29) . Further studies have revealed increased cathepsin activity in both hypertrophic and failing hearts (8, 31) and showed that cathepsins are regulated under these pathological conditions. CTSB (GenBank Accession No. AH001867.1) is both an endopeptidase and a carboxydipeptidase and is composed of a 15-residue putative signal peptide, a 75-residue propeptide, and a 249-residue mature domain. A CTSB gene containing 13 exons has been mapped to chromosome 8p22 (22b) . As with all other cathepsin members, CTSB is well recognized as a proteolytic enzyme, namely, an enzyme that plays an essential role in regulating innate immunity (23) , extracellular matrix balance (24) , inflammation, and apoptosis (11) . CTSB is reportedly involved in various pathologies and oncogenic processes in humans (22, 25) . Moreover, increased CTSB expression was reported in H9c2 cardiomyocytes in patients with doxorubicininduced cardiomyopathy (2) and in patients with heart failure secondary to dilated cardiomyopathy (12) . More recently, Liu et al. (17) found that a specific CTSB inhibitor, CA-074Me, significantly attenuated cardiac remodeling after myocardial infarction. This observation suggested that CTSB plays an important role in cardiovascular disease. However, whether CTSB affects chronic pressure overload-induced cardiac remodeling has never been examined. It is known that pressure overload can activate the renin-angiotensin system and induced the release of ANG II, which activates the G␣ (q) protein-coupled receptor signaling pathway (37) . Thus ANG II was used in vitro to induce the cardiac remodeling in cardiomyocytes. In this study, we used CTSB-knockout (KO) mice and cultured CTSB-deficient and CTSB-overexpressed H9c2 cardiomyocytes to investigate the role of CTSB in cardiac remodeling in response to hypertrophic stimuli. We show that eliminating CTSB reduces cardiac hypertrophy and CTSB is dynamically regulated during cardiac hypertrophy and remodeling.
MATERIALS AND METHODS
Animals and animal models. All animal procedures were performed in accordance with the Guide for the Care and Use of Laboratory Animals, published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996) and approved by the Animal Care and Use Committee of Renmin Hospital of Wuhan University (Protocol No. 00013274). All surgeries and subsequent analyses were performed in a blinded manner. Male and female CTSBϩ/Ϫ heterozygous mice, purchased from the Jackson Laboratory, were backcrossed for generations. After the identification of their gene type, CTSBϪ/Ϫ homozygous mice were used as the CTSB KO group, and wild-type (WT) mice were used as the control group. Male CTSB-KO mice, and their WT littermates, aged 8 -10 wk, were subjected to either aortic banding (AB) or a sham operation, as described previously (39) . The mice were euthanized by cervical dislocation 8 wk after surgery. The hearts and lungs of killed mice were harvested and weighed to compare heart weight/body weight (HW/BW, mg/g), lung weight/body weight (LW/BW, mg/g), and heart weight/tibia length (HW/TL, mg/mm) ratios between KO and WT mice.
Echocardiography and hemodynamics. Echocardiography was performed on anesthetized (1.5% isoflurane) mice using a MyLab 30CV ultrasound (Biosound Esaote) with a 10-MHz linear array ultrasound transducer. The LV was assessed in both parasternal long-axis and short-axis views at a frame rate of 120 Hz. End-systole and enddiastole were defined as the phases in which the smallest and largest areas of the LV were obtained. LV end-systolic diameter and LV end-diastolic diameter were measured via LV M-mode tracing with a sweep speed of 50 mm/s at the midpapillary muscle level.
Hemodynamics were measured in anesthetized (1.5% isoflurane) mice using cardiac catheterization. A microtip catheter transducer (SPR-839; Millar Instruments, Houston, TX) was inserted into the right carotid artery and advanced into the LV. Fifteen minutes after stabilization, pressure signals and heart rate were continuously recorded with a Millar Pressure-Volume System (MPVS-400; Millar Instruments) coupled with a Powerlab/4SP A/D converter and then stored and displayed on a personal computer. Data were processed using the PVAN data analysis software.
Histological analysis. Hearts were excised, placed immediately in 10% potassium chloride solution to ensure that they were stopped in diastole, washed with saline solution, placed in 10% formalin, and embedded in paraffin. Hearts were cut transversely and close to the apex to visualize the left and right ventricles. Several sections of each heart (4-to 5-m thick) were prepared and stained with either hematoxylin and eosin for histopathology or picrosirius red (PSR) for collagen deposition analysis, and they were then visualized by light microscopy. To measure myocyte cross-sectional area, the sections were stained with FITC-conjugated wheat germ agglutinin (Invitrogen) to visualize membranes and 4=-6-diamidino-2-phenylindole (DAPI) to visualize nuclei. A single myocyte was measured with a quantitative digital image analysis system (Image Pro-Plus, version 6.0). Between 100 and 200 LV myocytes were outlined in each group. The LV collagen volume fraction was calculated from the PSR-stained sections as the area stained by PSR divided by the total area.
Quantitative real-time RT-PCR. Total RNA was extracted from either frozen mouse cardiac tissue or cultured H9c2 cardiomyocytes using TRIzol (15596-026; Invitrogen). The RNA (2 g of each sample) was reverse-transcribed into cDNA using oligo (DT) primers and the Transcriptor First Strand cDNA Synthesis Kit (04896866001; Roche). PCR amplifications in all groups were quantified using a LightCycler 480 SYBR Green 1 Master Mix (04707516001; Roche), and the results were normalized against glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene expression.
Western blotting. Protein was extracted from cardiac tissue and cultured H9c2 cardiac myocytes in different groups and was measured using a BCA protein assay kit (Thermo, 23227, Synergy HT; BioTek). The cell lysate (50 g) was fractionated on 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), subsequently transferred onto an Immobilon-P membrane (Millipore, Bei- Assessment of apoptosis. Samples were first incubated with a terminal deoxynucleotide transferase-mediated dUTP nick end-labeling (TUNEL) reagent containing terminal deoxynucleotidyl transferase and fluorescent isothiocyanate-dUTP according to the protocol of the ApopTag Plus Fluorescein In Situ Apoptosis Detection Kit (S7111; Chemicon, Temecula, CA). Paraffin-embedded sections of mouse hearts were stained with DAPI for 30 min to evaluate the cell nucleus; meanwhile, the cells were costained with ␣-sarcomeric-actin. The numbers of apoptotic and total cells were counted, and the percentages of apoptotic cells were calculated by at least three independent individuals in a blinded manner.
Plasmid constructs. The pSicoR plasmid (no. 11597; Addgene), utilized for knockdown experiments in vitro, was used to construct the CTSB-specific (sh-CTSB) shRNA by cloning the annealed sense and antisense oligos to the HpaI and XhoI site of pSicoR. The sense and antisense oligos were as follow were as follows (sites of target sequence are underlined): CTSB-1#-F, TGCCATGTCTGACCGAATCT-GCTTCAAGAGAGCAGATTCGGTCAGACATGGCTTTTTTC, CTSB-1#-R, TCGAGAAAAAAGCCATGTCTGACCGAATCT-GCTCTCTTGAAGCAGATTCGGTCAGACATGGCA; CTSB-2#-F, TGATAAGCACTATGGGTACACTTCAAGAGAGTGTACCCATAG-TGCTTATCTTTTTTC CTSB-2#-R, TCGAGAAAAAAGATA-AGCACTATGGGTACACTCTCTTGAAGTGTACCCATAGTGCT-TATCA; CTSB-3#-F, TGATTCTAATCTGCTGGGACTTCAAGAGA-GTCCCAGCAGATTAGAATCTTTTTTC, CTSB-3#-R, TCGAGAA-AAAAGATTCTAATCTGCTGGGACTCTCTTGAAGTCCCAG-CAGATTAGAATCA.
In addition, the EGFP and the shRNA oligo are flanked by LoxP sites and therefore by expressing Cre recombinase can easily rescue the expression of the targeted gene (28, 34a) .
The rat CTSB overexpressing plasmid was cloned into psi-Flag-C1, which was utilized for overexpression experiments in vitro. Rat cDNA was PCR amplified using primers CTSB-5= (CGCG-GATCCATGTGGTGGTCCTTGATC) and CTSB-3= (CCGCTC-GAGTTAGAATCTTCCCCAGTACTG), digested by BamHI and XhoI, and ligated into psi-Flag-C1 to create Flag-VHL. The construct was verified by sequencing.
Virus generation and infection. Recombinant lentiviruses were produced by cotransfecting HEK293T cells in combination with the lentiviral packaging vectors pRSV-Rev, pMD2.G, and pCMV-VSV-G using Lipofectamine 2000. Briefly, 3 ϫ 10 6 cells were seeded in a 10-cm dish before transfection. For each 10-cm dish, 4 g shRNA-lentivirus plasmid, 2 g pRSV-Rev, 2 g pMD2.G, and 2 g pCMV-VSV-G were mixed with Lipofectamine 2000 in Opti-MEM and incubated at room temperature for 15 min. Transfection mixture was added to the cells and incubated for 8 h. The medium was then aspirated and fresh medium added to support virus growth. The culture medium containing infectious lentivirus was collected 48 h after transfection, centrifuged to remove cell debris, filtered through a 0.4-m filtration unit, and then used directly to infect H9c2 cells. CTSB expression in infected cells was validated by real-time PCR and Western blot assays after 72 h.
Cell culture. The H9c2 cardiomyocytes were obtained from Cell Bank of the Chinese Academy of Sciences, Shanghai, China, and grown in Dulbecco's modified Eagle's medium (DMEM; C11995; GIBCO,) supplemented with 10% fetal bovine serum (10099; GIBCO), penicillin (100 U/ml), and streptomycin (100 mg/ml; 15140; GIBCO) in an atmosphere of 5% CO 2 inside a humidified incubator (SANYO 18M) at 37°C. Exponentially growing cells were dissociated with 0.25% trypsin (25200; GIBCO) and seeded at a density of 1 ϫ 10 6 per well in six-well culture plates, 5.0 ϫ 10 3 per well in 24-well plates, or 10 ϫ 10 7 per well in 10-cm-diameter culture plates. Cells were incubated with ANG II (1 M; A9525; Sigma) for 24 h and subsequently cultured with serum-free DMEM.
Statistical analysis. All data are expressed as the means Ϯ SE and analyzed by one-way ANOVA, followed by either a post hoc Tukey test for analysis of any differences between groups or by an unpaired Student's t-test for between-group comparisons. A P value Ͻ 0.05 indicated a statistically significant difference.
RESULTS
CTSB expression in a pressure overload-induced hypertrophic mouse model. To investigate whether CTSB is involved in cardiac hypertrophy, we first examined CTSB expression in an experimental mouse model with AB-induced cardiac hypertrophy and in an vitro model induced by ANG II, we observed that the expression of CTSB was upregulated 1.77-fold in mouse hearts 2 wk after AB, 3.44-fold 4 wk after AB, and 4.27-fold 8 wk after AB compared with sham-operated hearts (Fig. 1A) . Furthermore, using cardiomyocytes treated with ANG II (1 M) for 24 h to induce hypertrophy, we found that the levels of CTSB were increased to 3.62-fold in these hypertrophic cardiomyocytes (Fig. 1B) . We also explored the localization of CTSB by using immunofluorescence and found that CTSB could be detected in the cytoplasm of cardiomyocytes in response to pressure overload and ANG II stimuli (Fig.  1C) . Together, these data indicate that CTSB is actually expressed in hearts and its protein levels are significantly increased in hypertrophic cardiomyocytes. This findings suggest that CTSB is involved in cardiac hypertrophy.
Absence of CTSB in hearts attenuates pressure overloadinduced cardiac hypertrophy. We used a CTSB-KO mouse model ( Fig. 2A) and subjected the mice to either AB or sham operation for 8 wk to evaluate the effect of CTSB on cardiac remodeling. After AB, CTSB-null hearts exhibited remarkable attenuation of cardiac hypertrophy, as evidenced by the following findings: gross heart shrinkage ( BW, LW/BW, and HW/TL (Fig. 2C ) compared with ABtreated WT hearts (CTSBϩ/ϩ). Similar decreases in wall thickness were also observed, as assessed with echocardiography by measuring interventricular septal thickness at both end-diastole and end-systole. LV contraction was significantly improved in CTSB-KO hearts, as determined by measuring both fractional shortening and LV ejection fraction (Fig. 2D) . Pressure-volume loop analysis further illustrated the improvements in LV hemodynamic dysfunction in CTSB-KO mice, as measured by parameters that reflect LV volume, systolic function, and diastolic function (Table 1) . Moreover, the mRNA expression levels of several hypertrophic markers, including ANP, brain natriuretic peptide (BNP), and ␤-MHC, were much lower in CTSB-KO mice, whereas the expression of a-MHC was much higher, compared with WT mice after AB (Fig. 2E) .
Absence of CTSB attenuates pressure overload-induced cardiac fibrosis. Cardiac fibrosis is an essential feature of pathological cardiac remodeling. PSR staining of cardiac tissue sections was used to quantify collagen volume. Dramatic perivascular and interstitial fibrosis was observed in WT mice in response to AB but was markedly limited in CTSB-KO mouse hearts (Fig. 3A) . The mRNA levels of the fibrotic markers collagen I␣ and collagen III were measured (Fig. 3B) . The protein expression levels of the MMP9 were decreased in CTSB-null hearts (Fig. 3C) . Our results consistently revealed a decreased fibrotic response in CTSB-KO mice. All these data indicate that the deletion of CTSB blocks pathological cardiac hypotrophy and cardiac fibrosis induced by chronic pressure overload.
CTSB regulates angiotensin II-induced H9c2 cardiomyocyte hypertrophy in vitro.
Given that the deletion of CTSB in vivo may attenuate the effects of pressure overload-induced cardiac hypertrophy, we subsequently performed in vitro studies using cultured H9c2 cardiomyocytes and subsequently established H9C2 cell lines with either stable expression of sh-CTSB or overexpression of CTSB using a lentiviral vector (lenti-CTSB) (Fig. 4A) . The stable cell lines were exposed to either ANG II (1 mol/l) or a PBS control for 24 h. Notably, the expression of neither sh-CTSB nor lenti-CTSB altered the size of cultured cardiomyocytes under basal PBS treatments compared with that of control cells. However, in response to ANG II-induced cell hypertrophy, the expression of sh-CTSB reduced the cell size (cross-sectional area) by 39.7% compared with the shRNA group (Fig. 4B) . Conversely, ANG II-induced cell hypertrophy was enhanced by 27.3% in lenti-CTSB cardiomyocytes compared with the negative control (lenti-NC) group (Fig. 4C) . We also examined the mRNA and protein expression of cardiac hypertrophic markers ANP, BNP, and ␤-MHC. Accordingly, the expression of the hypertrophy markers (ANP, BNP, and ␤-MHC) was dramatically suppressed in sh-CTSB-infected cardiomyocytes in response to ANG II (Fig. 4D ) but remarkably aggravated in lenti-CTSB-infected cardiomyocytes in response to ANG II (Fig. 4E) , compared with the controls. These in vitro data are consistent with the in vivo results and suggest that the downregulation of CTSB mitigates pathological cardiac hypertrophy, whereas the overexpression of CTSB promotes pathological cardiac hypertrophy.
CTSB regulates apoptosis. Cardiomyocyte apoptosis plays a critical role in pathological cardiac remodeling (21, 40) ; therefore, it may be very intriguing to examine whether altered CTSB expression interferes with apoptosis. Mouse hearts from each group were costained for TUNEL and ␣-actin to determine the effect of CTSB on cardiomyocyte apoptosis. CTSB-KO hearts exhibited an attenuation of apoptosis after 8 wk of AB compared with AB-treated WT hearts (Fig. 5A) . The antiapoptotic mechanisms of CTSB were assessed by Western blot analysis. We determined the expression levels of the apoptosis-related proteins Bcl-2, Bax, and Bid, as well as activated caspase signaling proteins, in both AB-induced remodeled hearts and ANG II-induced hypertrophic cardiomyocytes. We observed that CTSB-KO hearts displayed decreased expression of the proapoptotic proteins Bax and Bid, as well as increased expression of the antiapoptotic protein Bcl-2. Caspases are the primary drivers of apoptotic cell death, and our data showed that the activation of caspase 3 and caspase 9 was increased in AB WT mice but was blunted in CTSB-KO mice (Fig. 5B) . To confirm these findings, we used H9c2 cells featuring stable expression of either sh-CTSB or lenti-CTSB and H9c2 control cells, followed by treatment with ANG II or PBS for 24 h. Consistent with the in vivo results, Bax, Bid, activated caspase 3, and activated caspase 9 were downregulated and Bcl-2 was upregulated in sh-CTSB H9c2 cardiomyocytes in response to ANG II, compared with control cells (Fig. 5C ). In cells with lenti-CTSB, Bax, Bid, activated caspase 3, and activated caspase 9 were upregulated, and Bcl-2 was downregulated (Fig. 5D) . Collectively, these studies indicate that CTSB participates in the regulation of stress-induced cardiomyocyte survival, cardiac hypertrophy, and remodeling.
Effects of CTSB on TNF-␣/ASK1/JNK signaling. TNF-␣ is known to mediate apoptotic pathway in the myocardium after AB. Thus TNF-␣ provoked apoptotic signaling was examined. Consequently, our data indicated that TNF-␣, ASK1, JNK, c-Jun were significantly activated in AB mice, which increased Values are means Ϯ SE. CTSB, cathepsin B; WT, wild type; KO, knockout; AB, aortic banding; HR, heart rate; ESP, end-systolic pressure; EDP, end-diastolic pressure; ESV, end-systolic volume; EDV, end-diastolic volume; dp/dtmax, maximal rate of pressure development; dp/dtmin, maximal rate of pressure decay; CO, cardiac output. *P Ͻ 0.05 for difference from corresponding sham group. †P Ͻ 0.05 vs. WT AB group after AB. the release of cytochrome c. Also, CTSB deficiency inhibited the release of TNF-␣, and the activation of ASK1, JNK, c-Jun, and attenuated the release of cytochrome c (Fig. 6A) . Cardiac renin-angiotensin systems are known to be activated in the setting of pressure overload. In addition, ANG II can enhanced the expression of TNF-␣ via AT 1 and AT 2 receptors in hypertrophic cardiomyocytes (41). Thus we further confirmed the effect of CTSB on the TNF-␣ provoked apoptosis signaling in vitro. Notably, sh-CTSB-infected cardiomyocytes displayed decreased release of TNF-␣ and activation of ASK1, JNK, and c-Jun and reduced release of cytochrome c induced by ANG II, whereas lenti-CTSB-infected cardiomyocytes revealed enhanced release of TNF-␣ and phosphorylation of ASK1 and JNK c-Jun and the increased release of cytochrome c (Fig. 6,  B and C) . We investigated the activation of other members of MAPK in the CTSB-KO heart, a process induced by pressure overload. Our data indicated that extracellular signal-regulated kinase 1/2 (MEK-ERK1/2), p38, and Akt were significantly activated in AB mice; however, CTSB deficiency did not influence the phosphorylation of MEK-ERK1/2 or p38 compared with that in WT mice. Although Akt signaling plays a crucial role in the regulation of cardiac remodeling, we did not observe any differences in Akt activation between WT and KO mice ( Figure 6D) .
Effect of JNK inhibitor and CTSB inhibitor. To further confirm the effect of CTSB on JNK signaling, JNK inhibition SP600125 (10 M; S5567; Sigma) was used in lenti-CTSBinfected cardiomyocytes. CA074Me (10 M; C5857; Sigma), a cell-permeable cathepsin B inhibitor, was also used to verify whether its pharmacological effects are similar to those of sh-CTSB knockdown. Notably, SP600125 reduced the large cell size in CTSB overexpressed cardiomyocytes in response to ANG II. Furthermore, CA074Me exhibited the similar effects with sh-CTSB knockdown as assessed by measuring the cellsurface area and the mRNA expression levels of hypertrophic markers (Fig. 7, A and B) . SP600125 also reduced ANG II-induced increased phosphorylation of c-Jun and release of cytochrome c in CTSB overexpressed cardiomyocytes but did not affect the release of TNF-␣, and the activation of ASK1. CA074Me, similar to cells with sh-CTSB knockdown, blocked the cardiomyocytes apoptotic signaling induced by ANG II. All these data suggest that CTSB regulates cardiac remodeling through the TNF-␣/ASK1/JNK pathway (Fig. 7C ).
DISCUSSION
In this study, we focused on cardiac-enriched CTSB and found that CTSB plays a critical role in cardiomyocyte hypertrophy and cardiac remodeling in response to stress. We observed that the expression level of CTSB was gradually 
